Study of ALTO-101 in Patients With Schizophrenia
Public ClinicalTrials.gov record NCT06502964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment
Study identification
- NCT ID
- NCT06502964
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alto Neuroscience
- Industry
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Interventions
- ALTO-101 Drug
- ALTO-101 Transdermal Delivery System Device
- Placebo Drug
- Placebo Transdermal Delivery System Device
Drug · Device
Eligibility (public fields only)
- Age range
- 21 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2024
- Primary completion
- Jan 31, 2026
- Completion
- Feb 28, 2026
- Last update posted
- Dec 25, 2025
2024 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 5038 | Garden Grove | California | 92845 | Recruiting |
| Site 5063 | Los Angeles | California | 90015 | Recruiting |
| Site 5106 | Orange | California | 92868 | Recruiting |
| Site 5035 | Walnut Creek | California | 94596 | Recruiting |
| Site 5060 | Hollywood | Florida | 33024 | Recruiting |
| Site 5015 | Tampa | Florida | 33629 | Recruiting |
| Site 5064 | Snellville | Georgia | 30078 | Recruiting |
| Site 5056 | Chicago | Illinois | 60640 | Recruiting |
| Site 5062 | Gaithersburg | Maryland | 20877 | Recruiting |
| Site 5124 | Belmont | Massachusetts | 02478 | Recruiting |
| Site 5108 | New York | New York | 10027 | Recruiting |
| Site 5077 | New York | New York | 10032 | Recruiting |
| Site 5109 | New York | New York | 10035 | Withdrawn |
| Site 5126 | White Plains | New York | 10605 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06502964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 25, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06502964 live on ClinicalTrials.gov.